A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $10 from $18 and keeps an Outperform rating on the shares. The firm ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

DelveInsight's ' Gene Therapy Competitive Landscape – 2024 ' report provides comprehensive global coverage of available, ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Editas Medicine is ousting its ex vivo sickle cell and beta thalassemia gene therapy to instead focus on an in vivo treatment ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.